DIA 2013 49th Annual Meeting
Click here to go to the previous page
Human Abuse Liability Testing in CNS Drug Development
Track : Track 04: Nonclinical and Translational Development/Early Phase Clinical Development
Program Code: 247
Date: Tuesday, June 25, 2013
Time: 1:45 PM to 3:15 PM  EST
Location: 156C
CHAIR :
Lynn Roy Webster, MD (SCHNON), Medical Director, CRI Lifetree, United States
SPEAKER (S):
Lynn Roy Webster, MD (SPKNON), Medical Director, CRI Lifetree, United States
 Jack Henningfield, PhD (SPKNON), Vice President, Research, Health Policy, and Abuse Liabiliy, Pinney Associates, United States
Robert A. Medve, MD (SPKNON), Chief Medical Officer, Nektar Therapeutics, United States
Description
This workshop will address clinical aspects of conducting human abuse liability studies. It will provide insight on FDA's Draft Decision Tree on Assessment of Abuse Potential and the appropriate methodology for assessment of abuse liability potential.

**Due to workshop format, seating will be limited and will be available on a first come, first served basis.

The Boston Convention and Exhibition Center (BCEC) has stringent regulations on maximum room capacities, and they are strictly enforced. Once all seats are occupied, DIA will be required to close the workshop, and no more participants will be admitted. Interested attendees are encouraged to arrive at workshops early in order to ensure seating. Please note, as a workshop with interactivity, this event will not be recorded.